UK markets closed

Editas Medicine, Inc. (0IFK.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
45.60-4.37 (-8.75%)
At close: 5:43PM GMT
Sign in to post a message.
  • i
    iamaverb
    Tomorrows 8:00 a.m. ET cc to discuss the corporate update and results for the fourth quarter and full year of 2020 is the earliest the company has ever held a call. This early schedule gives the market plenty of time to digest the information before regular trading, and it has me wondering.
    Anybody care to make a prediction?
  • E
    EDIT
    For those of you who have been with EDITAS for more than 3 months, you will remember that on November 24 of 2020 we were trading at 29.02. Our best close came a 6 weeks later when we reached 90.58 on 1.8.2021. That push came because of C. Woods endorsement and EDIT 301 data that was shared by EDIT which place the speculative value of the stock up in the 90's. Fundamentally nothing has changed. Mismanagement of the EDIT 301 IND, the hold the FDA placed on it and the fall out from that which would have caused Charlie his job had he not resigned and which eventually caused Collins her job, have all contributed to us coming back down to this level. The sector is correcting but without those mishaps we should easily be around the upper sixties to low seventies at this moment. With good clinical data on EDIT 101 and correcting the EDIT 301 hold the FDA has placed on EDIT 301 testing ,we should be able to regain some market confidence and eventually make our way back to where we were six weeks ago. Its been a interesting last 12 weeks for this stock and its holders but we have tasted a little of the potential of this stock and this sector and you would be wise to remember the past and have patience going forward.
  • J
    Jim Jones
    After bashing this stock for months and doing lots of research, I took a long position today. (planning to hold 5+ years, invested $25k) I think a turnaround will come soon for $EDIT.
  • D
    DougF
    I found this quote from a yahoo listed article reassuring :

    "The Company expects that its existing cash, cash equivalents and marketable securities of $512 million at December 31, 2020, will enable it to fund its operating expenses and capital expenditures into 2023. This cash position does not include the $250 million of net proceeds from the public offering that occurred in early 2021."
  • E
    EDIT
    I really like Lisa Michaels. She is excellent in her presentations. Overall, unless we get some good clinical data in the upcoming March conferences there is nothing in todays CC that would help boost the stock.
  • E
    EDIT
    If you listened to the CC this morning, the new CEO shared his vision for the company and I for one think that he will partner with some deep pockets here soon to propel the pipeline further and that will give the market some added confidence in EDIT that will help the price of the stock. I expect to see some partnerships for EDIT 301 and 201 for sure before anything comes along for EDIT 101. Seems like they like to have control of that one. Michaels shared that they dosed the first mid dose EDIT 101 patient and it takes 4-6 to show reasonable results. Hopefully by the mid March conference or April conference they will clinical results to report.
  • O
    Offer
    CEO words moments before hanging up: "I look forward to sharing more data later this year." These guys know exactly what they are saying. I do not think he would have said that if he was not really looking forward to it which is only true if he thinks he has something positive to say.
  • E
    EDIT
    The price action today seems to reflect more the trend in the sector than anything to do with the CC. Maybe Bluebirds clinical data a while back ago started this downtrend in the sector? CRPS is bleeding and so are NTLA and BEAM. I would say only CRPS has been hit as hard as us but when the sector recovers, these will recover faster.
  • E
    EDIT
    With just a little positive nugget about EDIT 101 tomorrow, we can shoot up into the high 70's, perhaps maybe mid 80's. This new CEO might just pull the band aid around the entire EDIT 101 project and give us a little nugget. They had previously disclosed that they were going to report data at a health conference but they might briefly mention the status tomorrow with a full disclosure to come at a health conference. Usually these things don't add much other than we missed on revenue and another stock offering is coming, etc. but this time it might be different.
  • G
    George
    Personally holding at $61.50, after todays call continuing to hold due to the upcoming events at Cowen & Company 41st Annual Health Care Conference, March 1, and the Virtual, Barclays Global Healthcare Conference, March 10, Virtual. In the short term I remain neutral or even slightly bearish but give this whole sector time and god will we are back to new highs.
  • O
    Offer
    Don't forget... We only need one product from the big 4 to boost us all to the sky. Ppl want proof.
    Hold and add. I will add in 40, 50 or 80 dollars. The potential is huge.
  • i
    iamaverb
    As far as the depth of the information and the openness of the conversation compared to a Collins led call, I consider today a win.
  • S
    Stephen
    I thought I’d missed the chance to buy in at a decent price but said if the SP dipped to $50 I would jump in. So here I am joining the party late but ready for the next session. I believe EDIT has incredible potential and amazing future ahead so feeling lucky to get in at $50
  • i
    iamaverb
    The Mullen compensation agreement states:
    The Offer Letter provides for an annual base salary of $625,000 and an annual target bonus equal to 60% of his base salary, which bonus shall be prorated for 2021. Mr. Mullen will also receive a benefits allowance of $2,750 per month. In addition, the Company has agreed to grant Mr. Mullen (i) an option to purchase such number of shares of common stock having an aggregate Black-Scholes value of $10,000,000 as of the date of grant, which shall vest upon the achievement of specified organizational milestones to be determined by the Organization, Leadership and Compensation Committee (the “OLC Committee”) of the Board of Directors (the “New Hire Option”) at the time of grant, (ii) an option to purchase such number of shares of common stock having an aggregate Black-Scholes value, inclusive of a performance premium, of $5,000,000 as of the date of grant, which shall vest as to one-third of the shares underlying the option on the date on which the closing price of the Company’s common stock has for 15 consecutive trading days (in the five-year period following grant) equaled or exceeded $80.00, $100.00 and $120.00, respectively (the “Performance-Vesting Option”) and (iii) a restricted stock unit award for such number of shares of common stock having an aggregate value of $5,000,000 as of the date of grant which shall vest as to one-third of the shares on the achievement of certain research and development milestones to be determined by the OLC Committee (the “RSU Award”) at the time of grant.

    I am beginning to get confidence in Editas again with only 3 more trading days left till the cc.
  • A
    Anonymous
    Maybe I should have been in more of a hurry to load up on BEAM... I’m hoping for some strong and confident guidance from Mullen in this CC. Clear execution is past due and the investors are currently paying for it.
  • G
    GreenLeader
    So if I read that correctly some kind of success with Edit 101 without saying anything.
  • A
    Anonymous
    So May 1-7 is an ocular conference, could that be the data presentation for EDIT-101?
  • M
    Mick
    Except from Albright’s latest interview. I’m not gonna chime in other than post and leave interpretation to the reader.

    “” “We’re really at the beginning of a new era of drug development with gene therapy,” Albright tells me, pointing to some big advances, as well as acknowledging some daunting setbacks that have occurred.

    It’s not surprising we’re seeing both successes and some setbacks,” he adds. “I came to Affinia because I thought we had the potential to address some of the fundamental issues in AAV gene therapy. And after my first 4 weeks here I believe that even more than when I took the job.

    ... The big idea at Affinia, what attracted Albright to the company, is the belief that the insights Luk Vandenberghe made in his Harvard lab can translate into new and much better capsids that can significantly improve efficacy, guard against toxicity and target a variety of new tissues that can open the door to a host of diseases now outside the reach of the currently available tech. The tech also has the potential to avoid resistance mechanisms, naturally reoccurring antibodies, and help solve manufacturing challenges. “”
  • E
    EDIT
    Moving forward there is no way but up after a 50% pullback but that is not a healthy sign for any stock and that is not a bullish trend. That is definitely a sector shift from bullish to bearish. We are seeing some 40%-50% pullbacks among other stocks in the sector and that indicates a massive correction in the sector as a whole. Going forward it shows that any growth explosion could be met by a blow off top like that again. That is not usually seen in stocks of this magnitude. Could be attributed to the uncertainty of the growth potential of the sector. We thought we had clarity with CRSPR clinical data but apparently the market still wants more proof.
  • E
    EDIT
    If you haven't seen this video, its worth watching. It gives a little glimpse of what the wales do on a daily basis and you can see this happening right now in this sector. https://www.youtube.com/watch?v=W90V_DyPJTs&ab_channel=DayTradeToWin
    Market Manipulation - Do You Think This is Fair? - It Happens Every Trading Day
    www.youtube.com